NASDAQ Biotechnology Index


Also found in: Wikipedia.

NASDAQ Biotechnology Index

An index tracking pharmaceutical, biological research and similar companies whose shares trade on NASDAQ. It is weighted under a modified market capitalization scheme; the securities that compose it are updated semi-annually.
References in periodicals archive ?
M2 PHARMA-December 19, 2017-GlycoMimetics to Join NASDAQ Biotechnology Index
declared that it has been chosen or inclusion to the NASDAQ Biotechnology Index.
The Nasdaq Biotechnology Index is a modified capitalization-weighted index that includes Nasdaq-listed companies classified as either biotechnology or pharmaceutical.
After a year of remarkable gains--accentuated by a near-record number of initial public offerings (IPOs) and 61 percent rise in the NASDAQ Biotechnology Index (the gain is more than double the S&P 500's 26 percent growth in 2013)--biotech stocks have significantly lost their luster.
The Nasdaq biotechnology index fell seven per cent for the week.
Biotechnology companies in particular had a standout 2013, with the Nasdaq Biotechnology Index gaining 66 per cent, topping a 30 per cent increase for the Standard & Poor's 500, and closing on Thursday at a record high of 2,449.
M2 EQUITYBITES-December 24, 2013-Agios Pharmaceuticals announces addition to Nasdaq Biotechnology Index
The firm cites the iShares NASDAQ biotechnology Index, the SPDR S&P Biotech ETF and the First Trust AMEX biotechnology Index ETF, which have all gained over 20% in the past year and outperformed the broader markets by a good margin.
The ETFs seek to provide 200 per cent or -200 per cent of the return of the NASDAQ Biotechnology Index for a single day.
AVANIR Pharmaceuticals has been selected for addition to the NASDAQ Biotechnology Index effective Monday, November 20.